-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Annovis Bio, Lowers Price Target to $17

Benzinga·05/15/2025 12:14:44
Listen to the news
Canaccord Genuity analyst Sumant Kulkarni maintains Annovis Bio (NYSE:ANVS) with a Buy and lowers the price target from $26 to $17.